Study on the Effectiveness of EGb 761® vs Placebo Used for Cognitive Impairment in Patients With Multiple Sclerosis

Inclusion Criteria: * Patient with Multiple Sclerosis Relapsing-Remitting form * Patient with cognitive impairment (as spontaneous complaint by either patient or family) * Patient treated with interferon and maintaining same dosage for previous 6 months * Patient without major disability (Kurtzke Extended Disability Status Scale ≤6) Exclusion Criteria: * Clinical Multiple Sclerosis relapse within 3 months prior to participation * Major psychiatric disease according to Diagnostic and Statistical Manual of Mental Disorders, 4th Ed. * Other concomitant disorders possibly jeopardizing the cognitive status evaluation or the follow up of the patient (severe impairment of visual or motor function which may prevent participation in neuropsychological testing)